Therefore, we believe that CD97 may affect the progression of HCC and the prognosis of patients by altering the expression of immune checkpoint genes such as TOX, PD-L1, PD-L2, CTLA4, and PD-1. This evidence concerns the gene PDCD1LG2 and hepatocellular carcinoma.